Telik, Inc. (Nasdaq: TELK | Quote | Chart | News | PowerRating) , sector: Healthcare . industry: Pharmaceuticals - Generic & Specialty
June 04,2009- Telik, Inc. (Nasdaq: TELK | Quote | Chart | News | PowerRating) announced that company management will provide a corporate overview at the Eighth Annual Needham Life Sciences Conference in New York City on Wednesday, June 10, 2009 at 10:30 a.m. Eastern time (7:30 a.m. Pacific time). A live and archived webcast of the presentation will be available on the Telik website, www.telik.com.
Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer and inflammatory diseases. The company's most advanced investigational drug candidates in clinical development are TELINTRA(R), a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA(R), a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP(R), which enables the rapid and efficient discovery of small molecule drug candidates.
About ESR: Emerging Stock Report is a leading provider of independent investment research in North America our services include, research analysis on the small cap markets, real time news and financial data, market commentary and the ESR newsletter .Emerging Stock Report's staff of small cap investment professionals is dedicated to providing the emerging market's investment community with the tools and avenues necessary to make the important investment decisions. To view our research reports on a complimentary trial basis and take advantage of our other services go to www.emergingstockreport.com and click on the complimentary trial subscription button on our home page, or go directly to our registration page at www.emergingstockreport.com/register.php
ESR Disclosure: Emerging Stock Report is not a registered investment advisor and nothing in this release should be construed as a recommendation to buy or sell securities. Emerging Stock Report has not been compensated by the above mentioned companies.
CONTACT: Emerging Stock Report e-mail: info@emergingstockreport.com
((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index